Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature
Angiosarcoma represents 1 to 2% of soft tissue tumors. It originates from endothelial cells of small blood vessels and may affect a variety of organs, including the retroperitoneum, skeletal muscle, subcutis, liver, heart and breast. The outcome of angiosarcoma is poor for those patients in whom agg...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2008-09, Vol.28 (5B), p.3041-3045 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3045 |
|---|---|
| container_issue | 5B |
| container_start_page | 3041 |
| container_title | Anticancer research |
| container_volume | 28 |
| creator | ASMANE, Irène LITIQUE, Valère HEYMANN, Steve MARCELLIN, Luc METIVIER, Anne-Cécile DUCLOS, Brigitte BERGERAT, Jean-Pierre KURTZ, Jean-Emmanuel |
| description | Angiosarcoma represents 1 to 2% of soft tissue tumors. It originates from endothelial cells of small blood vessels and may
affect a variety of organs, including the retroperitoneum, skeletal muscle, subcutis, liver, heart and breast. The outcome
of angiosarcoma is poor for those patients in whom aggressive surgery cannot be considered. Chemotherapy, generally consisting
of the combination of anthracyclines and ifosfamide, has little, but consistent effect. We report three cases of angiosarcoma
in which first-line chemotherapy with adriamycin 40 mg/m 2 day 1, ifosfamide 3 g/m 2 day 1-2, cisplatin 35 mg/m 2 day 1-2 and paclitaxel 175 mg/m 2 day 3 led to clinically meaningful responses. The clinical relevance of incorporating paclitaxel in conventional soft tissue
chemotherapy schedules in the light of both literature data and our experience is discussed. We emphasize the need for designing
trials specifically dedicated to angiosarcomas, as this rare and severe condition may be a target for new antiangiogenic drugs. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69828391</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69828391</sourcerecordid><originalsourceid>FETCH-LOGICAL-h270t-c797b2fa4619c275df5d8abdc3cbb7cfa02f1eaca618ccd58f52796c790620e93</originalsourceid><addsrcrecordid>eNpFkM1u1DAUhSMEotOWV0DewIogx578eDlELa00CFS16-jGvm6MHDvYnpY8IO-FWwZY-Vr6zjnS96LYVK2oyrbm9GWxoaymZUtpfVKcxvid0qYRHX9dnFSC8krUfFP82qlgYF6lcR9Ib-JiIT2d19pHDbNRSMAp8g2kNQl-oiW9n0fjMuUdgUgug3eptMYh6SecfZowwLIS7QPZewnWrmSnHsBJVM9VXzBBTDkvyc7dGx8hSD_Dx_wDu0YTidfkdgqYCyEiucHFhxSfszf4YPDxCcgzZG9S3kqHgOfFKw024pvje1bcXV7c9lfl_uvn6363LyfW0lTKVrQj07BtKiFZWytdqw5GJbkcx1ZqoExXCBKaqpNS1Z2uWSuaHKMNoyj4WfH-T-8S_I8DxjTMJkq0Fhz6QxyyXtZxUWXw7RE8jDOqYQlmhrAOf8Vn4N0RgJgl6ZAFmfiPY7Sj223D_i9O5n56NAGHOGenuZYPEFg31J8GTrcV_w2SEZ5l</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69828391</pqid></control><display><type>article</type><title>Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>ASMANE, Irène ; LITIQUE, Valère ; HEYMANN, Steve ; MARCELLIN, Luc ; METIVIER, Anne-Cécile ; DUCLOS, Brigitte ; BERGERAT, Jean-Pierre ; KURTZ, Jean-Emmanuel</creator><creatorcontrib>ASMANE, Irène ; LITIQUE, Valère ; HEYMANN, Steve ; MARCELLIN, Luc ; METIVIER, Anne-Cécile ; DUCLOS, Brigitte ; BERGERAT, Jean-Pierre ; KURTZ, Jean-Emmanuel</creatorcontrib><description>Angiosarcoma represents 1 to 2% of soft tissue tumors. It originates from endothelial cells of small blood vessels and may
affect a variety of organs, including the retroperitoneum, skeletal muscle, subcutis, liver, heart and breast. The outcome
of angiosarcoma is poor for those patients in whom aggressive surgery cannot be considered. Chemotherapy, generally consisting
of the combination of anthracyclines and ifosfamide, has little, but consistent effect. We report three cases of angiosarcoma
in which first-line chemotherapy with adriamycin 40 mg/m 2 day 1, ifosfamide 3 g/m 2 day 1-2, cisplatin 35 mg/m 2 day 1-2 and paclitaxel 175 mg/m 2 day 3 led to clinically meaningful responses. The clinical relevance of incorporating paclitaxel in conventional soft tissue
chemotherapy schedules in the light of both literature data and our experience is discussed. We emphasize the need for designing
trials specifically dedicated to angiosarcomas, as this rare and severe condition may be a target for new antiangiogenic drugs.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 19031953</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Bone Neoplasms - drug therapy ; Breast Neoplasms - drug therapy ; Cisplatin - administration & dosage ; Doxorubicin - administration & dosage ; Female ; Hemangiosarcoma - drug therapy ; Humans ; Ifosfamide - administration & dosage ; Lumbar Vertebrae ; Male ; Medical sciences ; Middle Aged ; Paclitaxel - administration & dosage ; Soft Tissue Neoplasms - drug therapy ; Tumors ; Young Adult</subject><ispartof>Anticancer research, 2008-09, Vol.28 (5B), p.3041-3045</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20804462$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19031953$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ASMANE, Irène</creatorcontrib><creatorcontrib>LITIQUE, Valère</creatorcontrib><creatorcontrib>HEYMANN, Steve</creatorcontrib><creatorcontrib>MARCELLIN, Luc</creatorcontrib><creatorcontrib>METIVIER, Anne-Cécile</creatorcontrib><creatorcontrib>DUCLOS, Brigitte</creatorcontrib><creatorcontrib>BERGERAT, Jean-Pierre</creatorcontrib><creatorcontrib>KURTZ, Jean-Emmanuel</creatorcontrib><title>Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Angiosarcoma represents 1 to 2% of soft tissue tumors. It originates from endothelial cells of small blood vessels and may
affect a variety of organs, including the retroperitoneum, skeletal muscle, subcutis, liver, heart and breast. The outcome
of angiosarcoma is poor for those patients in whom aggressive surgery cannot be considered. Chemotherapy, generally consisting
of the combination of anthracyclines and ifosfamide, has little, but consistent effect. We report three cases of angiosarcoma
in which first-line chemotherapy with adriamycin 40 mg/m 2 day 1, ifosfamide 3 g/m 2 day 1-2, cisplatin 35 mg/m 2 day 1-2 and paclitaxel 175 mg/m 2 day 3 led to clinically meaningful responses. The clinical relevance of incorporating paclitaxel in conventional soft tissue
chemotherapy schedules in the light of both literature data and our experience is discussed. We emphasize the need for designing
trials specifically dedicated to angiosarcomas, as this rare and severe condition may be a target for new antiangiogenic drugs.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>Hemangiosarcoma - drug therapy</subject><subject>Humans</subject><subject>Ifosfamide - administration & dosage</subject><subject>Lumbar Vertebrae</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Paclitaxel - administration & dosage</subject><subject>Soft Tissue Neoplasms - drug therapy</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1u1DAUhSMEotOWV0DewIogx578eDlELa00CFS16-jGvm6MHDvYnpY8IO-FWwZY-Vr6zjnS96LYVK2oyrbm9GWxoaymZUtpfVKcxvid0qYRHX9dnFSC8krUfFP82qlgYF6lcR9Ib-JiIT2d19pHDbNRSMAp8g2kNQl-oiW9n0fjMuUdgUgug3eptMYh6SecfZowwLIS7QPZewnWrmSnHsBJVM9VXzBBTDkvyc7dGx8hSD_Dx_wDu0YTidfkdgqYCyEiucHFhxSfszf4YPDxCcgzZG9S3kqHgOfFKw024pvje1bcXV7c9lfl_uvn6363LyfW0lTKVrQj07BtKiFZWytdqw5GJbkcx1ZqoExXCBKaqpNS1Z2uWSuaHKMNoyj4WfH-T-8S_I8DxjTMJkq0Fhz6QxyyXtZxUWXw7RE8jDOqYQlmhrAOf8Vn4N0RgJgl6ZAFmfiPY7Sj223D_i9O5n56NAGHOGenuZYPEFg31J8GTrcV_w2SEZ5l</recordid><startdate>20080901</startdate><enddate>20080901</enddate><creator>ASMANE, Irène</creator><creator>LITIQUE, Valère</creator><creator>HEYMANN, Steve</creator><creator>MARCELLIN, Luc</creator><creator>METIVIER, Anne-Cécile</creator><creator>DUCLOS, Brigitte</creator><creator>BERGERAT, Jean-Pierre</creator><creator>KURTZ, Jean-Emmanuel</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20080901</creationdate><title>Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature</title><author>ASMANE, Irène ; LITIQUE, Valère ; HEYMANN, Steve ; MARCELLIN, Luc ; METIVIER, Anne-Cécile ; DUCLOS, Brigitte ; BERGERAT, Jean-Pierre ; KURTZ, Jean-Emmanuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h270t-c797b2fa4619c275df5d8abdc3cbb7cfa02f1eaca618ccd58f52796c790620e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>Hemangiosarcoma - drug therapy</topic><topic>Humans</topic><topic>Ifosfamide - administration & dosage</topic><topic>Lumbar Vertebrae</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Paclitaxel - administration & dosage</topic><topic>Soft Tissue Neoplasms - drug therapy</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ASMANE, Irène</creatorcontrib><creatorcontrib>LITIQUE, Valère</creatorcontrib><creatorcontrib>HEYMANN, Steve</creatorcontrib><creatorcontrib>MARCELLIN, Luc</creatorcontrib><creatorcontrib>METIVIER, Anne-Cécile</creatorcontrib><creatorcontrib>DUCLOS, Brigitte</creatorcontrib><creatorcontrib>BERGERAT, Jean-Pierre</creatorcontrib><creatorcontrib>KURTZ, Jean-Emmanuel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ASMANE, Irène</au><au>LITIQUE, Valère</au><au>HEYMANN, Steve</au><au>MARCELLIN, Luc</au><au>METIVIER, Anne-Cécile</au><au>DUCLOS, Brigitte</au><au>BERGERAT, Jean-Pierre</au><au>KURTZ, Jean-Emmanuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2008-09-01</date><risdate>2008</risdate><volume>28</volume><issue>5B</issue><spage>3041</spage><epage>3045</epage><pages>3041-3045</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Angiosarcoma represents 1 to 2% of soft tissue tumors. It originates from endothelial cells of small blood vessels and may
affect a variety of organs, including the retroperitoneum, skeletal muscle, subcutis, liver, heart and breast. The outcome
of angiosarcoma is poor for those patients in whom aggressive surgery cannot be considered. Chemotherapy, generally consisting
of the combination of anthracyclines and ifosfamide, has little, but consistent effect. We report three cases of angiosarcoma
in which first-line chemotherapy with adriamycin 40 mg/m 2 day 1, ifosfamide 3 g/m 2 day 1-2, cisplatin 35 mg/m 2 day 1-2 and paclitaxel 175 mg/m 2 day 3 led to clinically meaningful responses. The clinical relevance of incorporating paclitaxel in conventional soft tissue
chemotherapy schedules in the light of both literature data and our experience is discussed. We emphasize the need for designing
trials specifically dedicated to angiosarcomas, as this rare and severe condition may be a target for new antiangiogenic drugs.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>19031953</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2008-09, Vol.28 (5B), p.3041-3045 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69828391 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone Neoplasms - drug therapy Breast Neoplasms - drug therapy Cisplatin - administration & dosage Doxorubicin - administration & dosage Female Hemangiosarcoma - drug therapy Humans Ifosfamide - administration & dosage Lumbar Vertebrae Male Medical sciences Middle Aged Paclitaxel - administration & dosage Soft Tissue Neoplasms - drug therapy Tumors Young Adult |
| title | Adriamycin, Cisplatin, Ifosfamide and Paclitaxel Combination as Front-line Chemotherapy for Locally Advanced and Metastatic Angiosarcoma. Analysis of Three Case Reports and Review of the Literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T00%3A41%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adriamycin,%20Cisplatin,%20Ifosfamide%20and%20Paclitaxel%20Combination%20as%20Front-line%20Chemotherapy%20for%20Locally%20Advanced%20and%20Metastatic%20Angiosarcoma.%20Analysis%20of%20Three%20Case%20Reports%20and%20Review%20of%20the%20Literature&rft.jtitle=Anticancer%20research&rft.au=ASMANE,%20Ir%C3%A8ne&rft.date=2008-09-01&rft.volume=28&rft.issue=5B&rft.spage=3041&rft.epage=3045&rft.pages=3041-3045&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E69828391%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69828391&rft_id=info:pmid/19031953&rfr_iscdi=true |